Controlled trial of Maintenance versus No Maintenance Chemotherapy in the treatment of Small-cell lung cancer.

N M Bleehen, P M Fayers, D J Girling, R J Stephens

Research output: Contribution to journalAbstract

1 Citation (Scopus)

Abstract

A total of 544 patients was entered into a study in which 505 with small cell lung
cancer and good performances status were assessable. They were all prescribed an initial six courses of etoposide 120 mg/M2, cyclophosphamide lg/m2, methotrexate 35 mg/M2, and vincristine 1.3 mg/M2 (max 2 mg) intravenously on day 1, plus etoposide 240 mg/M2 by mouth on days 2 and 3, at 3 weekly intervals. Patients with limited disease received radiotherapy, 40 Gy in 15 fractions in 3 weeks, of the primary site between courses 2 and 3. Response rates three weeks after the second course were complete in 10% and partial in 72%. Treatment was well tolerated. At the end of the initial courses, patients in
complete or partial response (total 266) were randomised to maintenance (six more courses of the same drugs) or no maintenance chemotherapy. There was no survival advantage to either series.
Original languageEnglish
Pages (from-to)699
Number of pages1
JournalThorax
Volume40
Issue number9
DOIs
Publication statusPublished - Sep 1985

Fingerprint

Maintenance Chemotherapy
Small Cell Lung Carcinoma
Maintenance
Etoposide
Vincristine
Methotrexate
Cyclophosphamide
Mouth
Radiotherapy
Therapeutics
Survival
Pharmaceutical Preparations

Cite this

Controlled trial of Maintenance versus No Maintenance Chemotherapy in the treatment of Small-cell lung cancer. / Bleehen, N M; Fayers, P M; Girling, D J; Stephens, R J.

In: Thorax, Vol. 40, No. 9, 09.1985, p. 699.

Research output: Contribution to journalAbstract

@article{72b078278912485ba1a9344a1194c5ee,
title = "Controlled trial of Maintenance versus No Maintenance Chemotherapy in the treatment of Small-cell lung cancer.",
abstract = "A total of 544 patients was entered into a study in which 505 with small cell lungcancer and good performances status were assessable. They were all prescribed an initial six courses of etoposide 120 mg/M2, cyclophosphamide lg/m2, methotrexate 35 mg/M2, and vincristine 1.3 mg/M2 (max 2 mg) intravenously on day 1, plus etoposide 240 mg/M2 by mouth on days 2 and 3, at 3 weekly intervals. Patients with limited disease received radiotherapy, 40 Gy in 15 fractions in 3 weeks, of the primary site between courses 2 and 3. Response rates three weeks after the second course were complete in 10{\%} and partial in 72{\%}. Treatment was well tolerated. At the end of the initial courses, patients incomplete or partial response (total 266) were randomised to maintenance (six more courses of the same drugs) or no maintenance chemotherapy. There was no survival advantage to either series.",
author = "Bleehen, {N M} and Fayers, {P M} and Girling, {D J} and Stephens, {R J}",
year = "1985",
month = "9",
doi = "10.1136/thx.40.9.688",
language = "English",
volume = "40",
pages = "699",
journal = "Thorax",
issn = "0040-6376",
publisher = "BMJ Publishing Group Ltd",
number = "9",

}

TY - JOUR

T1 - Controlled trial of Maintenance versus No Maintenance Chemotherapy in the treatment of Small-cell lung cancer.

AU - Bleehen, N M

AU - Fayers, P M

AU - Girling, D J

AU - Stephens, R J

PY - 1985/9

Y1 - 1985/9

N2 - A total of 544 patients was entered into a study in which 505 with small cell lungcancer and good performances status were assessable. They were all prescribed an initial six courses of etoposide 120 mg/M2, cyclophosphamide lg/m2, methotrexate 35 mg/M2, and vincristine 1.3 mg/M2 (max 2 mg) intravenously on day 1, plus etoposide 240 mg/M2 by mouth on days 2 and 3, at 3 weekly intervals. Patients with limited disease received radiotherapy, 40 Gy in 15 fractions in 3 weeks, of the primary site between courses 2 and 3. Response rates three weeks after the second course were complete in 10% and partial in 72%. Treatment was well tolerated. At the end of the initial courses, patients incomplete or partial response (total 266) were randomised to maintenance (six more courses of the same drugs) or no maintenance chemotherapy. There was no survival advantage to either series.

AB - A total of 544 patients was entered into a study in which 505 with small cell lungcancer and good performances status were assessable. They were all prescribed an initial six courses of etoposide 120 mg/M2, cyclophosphamide lg/m2, methotrexate 35 mg/M2, and vincristine 1.3 mg/M2 (max 2 mg) intravenously on day 1, plus etoposide 240 mg/M2 by mouth on days 2 and 3, at 3 weekly intervals. Patients with limited disease received radiotherapy, 40 Gy in 15 fractions in 3 weeks, of the primary site between courses 2 and 3. Response rates three weeks after the second course were complete in 10% and partial in 72%. Treatment was well tolerated. At the end of the initial courses, patients incomplete or partial response (total 266) were randomised to maintenance (six more courses of the same drugs) or no maintenance chemotherapy. There was no survival advantage to either series.

U2 - 10.1136/thx.40.9.688

DO - 10.1136/thx.40.9.688

M3 - Abstract

VL - 40

SP - 699

JO - Thorax

JF - Thorax

SN - 0040-6376

IS - 9

ER -